Moderna has delivered one of its strongest weekly performances of the year, up 16% to $55.40, yet short sellers have barely flinched — and that contradiction is the story this week.
Short interest is elevated and sticky. At nearly 15% of free float, it remains one of the higher readings in the biotech space, and the weekly change has been essentially flat — up just 1.3% despite the price move. That means shorts are absorbing paper losses rather than covering. The ORTEX short score sits at 69.3, a level that has held in a tight band all week, underscoring the persistence of bearish conviction. Days-to-cover of 12.3 adds a real cost to maintaining these positions through a price spike of this magnitude.
The lending market tells a more relaxed story. Borrow availability runs at roughly 291% — meaning there are nearly three shares available to lend for every one currently borrowed — comfortably above the 52-week low of 196%. Cost to borrow is a low 0.49%, up modestly on the week but still barely a rounding error for professional short sellers. There is no squeeze pressure here: plenty of supply, low cost, and no sign of the borrow pool tightening. Options positioning echoes the same calm. The put/call ratio at 0.90 is actually running slightly below its 20-day average of 0.92, with a z-score near -1.4 — meaning options traders are fractionally less defensive than usual, not more. The rally has not triggered a rush for protection.
The Street remains firmly on the sidelines. The consensus is a hold, with 17 analysts neutral and just one outperform. BofA Securities raised its target to $34 on June 8 while keeping an Underperform rating — a data point that now looks conspicuously below the current $55.40 price. Goldman Sachs moved to $49 in early May, and UBS to $45, both maintaining neutral views. Piper Sandler is the lone bull with a $69 target. The collective posture is one of cautious acknowledgment rather than enthusiasm: targets have been revised upward but remain clustered well below where the stock is trading, suggesting much of the move is running ahead of fundamental conviction. Factor scores back this up — the analyst recommendation differential ranks in the bottom 6th percentile, earnings momentum over 30 days is weak at the 14th percentile, and the short score rank sits at the 13th percentile.
The institutional picture has one genuinely notable data point. FMR (Fidelity) reported adding 17.6 million shares as of April 30, pushing its stake to nearly 11.5% of shares outstanding — a substantial and relatively recent accumulation. Capital Research also added 5.9 million shares through late May. Against that, Morgan Stanley trimmed by 842,000 shares in Q1. The FMR build is the most significant flow in the holder table and provides a plausible source of demand that could be running counter to the short book.
On earnings, the most recent print — Q1 released in early May — produced a 3.9% gain the next day and a 7.9% gain over the following week, with Q4 before that delivering a 18% five-day move. The next event is August 6. With shorts sitting heavy and price targets clustered well below the current level, how the stock behaves in the six weeks between now and that release — particularly whether short sellers begin covering or dig in further — is the clearest signal to track.
See the live data behind this article on ORTEX.
Open MRNA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
